Bringing a new therapy to market is one of the riskiest bets in pharma, nearly one in three launches falls short of expectations, while 60% underperform when multiple therapies compete in the same space. Competitive intelligence (CI) isn’t just a tactical tool, when integrated early and continuously across development, it guides trial design, shapes payer strategy, and equips commercial teams to pivot ahead of competitive threats.
